| When: Monday, 11/4/2024, 3:30 pm - 5:00 pm |
| Where: Henry B. Gonzalez Convention Center-007 |
| Credits: 1.5 CME_Physicians Credits |
| Credits: 1.5 CME_OtherProfessions Credits |
Description: The development of highly-effective anti-obesity medications has highlighted ethical and economic challenges, particularly regarding health equity. High drug costs and a lack of insurance coverage pose significant barriers to access, disproportionately affecting socioeconomically disadvantaged populations who are already more susceptible to obesity and its health complications. Who should bear the responsibility of ensuring that these potentially life-saving treatments are accessible to all, regardless of income?
|
| Delivery Mechanism: Live In-Person |
| Keyword: Policy: Health Care Access; Policy: Health Equity; Treatment: Pharmacotherapy |
Track: Sub-track: Advancing Equitable Care; Track 3: Interventional and Clinical Studies
|
|
Speakers:
 | Sarah Ro, MD | Session Chair | |  | Arthur L. Caplan, PhD | Ethical Challenges | 3:30 pm - 3:50 pm |  | Robert Siegel, MD, MS | Follow the Money: Economic and Pharmacoequity Issues in the New Era of Anti-Obesity Medications | 3:50 pm - 4:10 pm |  | John Lewis | The Promise of Policy Change: Analysis of California Senate Bill 839 | 4:10 pm - 4:30 pm | | Sarah Ro, MD | Moderate Panel Q&A | 4:30 pm - 5:00 pm | | Arthur L. Caplan, PhD | Panel Q&A | 4:30 pm - 5:00 pm | | John Lewis | Panel Q&A | 4:30 pm - 5:00 pm | | Robert Siegel, MD, MS | Panel Q&A | 4:30 pm - 5:00 pm |
|
|
| Learning Objective: Apply the latest recommendations for evaluation and treatment; tailor intervention strategies based on patient characteristics such as age or metabolic or behavioral phenotype; understand the differences between weight loss and weight loss maintenance. |
|
|